AIM: Little is known regarding the steady-state uptake of drugs into the human myocardium. Perhexiline is a prophylactic anti-anginal drug which is increasingly also used in the treatment of heart failure and hypertrophic cardiomyopathy. We explored the relationship between plasma perhexiline concentrations and its uptake into the myocardium. METHODS: Blood, right atrium ± left ventricle biopsies were obtained from patients treated with perhexiline for a median of 8.5 days before undergoing coronary surgery in the perhexiline arm of a randomized controlled trial. Perhexiline concentrations in plasma and heart tissue were determined by HPLC. RESULTS: Atrial biopsies were obtained from 94 patients and ventricular biopsies from 28 patients. The median plasma perhexiline concentration was within the therapeutic range at 0.24 mg l⁻¹ (IQR 0.12-0.44), the median atrial concentration was 6.02 mg kg⁻¹ (IQR 2.70-9.06) and median ventricular concentration was 10.0 mg kg⁻¹ (IQR 5.76-13.1). Atrial (r² = 0.76) and ventricular (r² = 0.73) perhexiline concentrations were closely and directly correlated with plasma concentrations (both P < 0.001). The median atrial : plasma ratio was 21.5 (IQR 18.1-27.1), ventricular : plasma ratio was 34.9 (IQR 24.5-55.2) and ventricular : atrial ratio was 1.67 (IQR 1.39-2.22). Using multiple regression, the best model for predicting steady-state atrial concentration included plasma perhexiline, heart rate and age (r² = 0.83). Ventricular concentrations were directly correlated with plasma perhexiline concentration and length of therapy (r² = 0.84). CONCLUSIONS: This study demonstrates that plasma perhexiline concentrations are predictive of myocardial drug concentrations, a major determinant of drug effect. However, net myocardial perhexiline uptake is significantly modulated by patient age, potentially via alteration of myocardial:extracardiac drug uptake.
AIM: Little is known regarding the steady-state uptake of drugs into the human myocardium. Perhexiline is a prophylactic anti-anginal drug which is increasingly also used in the treatment of heart failure and hypertrophic cardiomyopathy. We explored the relationship between plasma perhexiline concentrations and its uptake into the myocardium. METHODS: Blood, right atrium ± left ventricle biopsies were obtained from patients treated with perhexiline for a median of 8.5 days before undergoing coronary surgery in the perhexiline arm of a randomized controlled trial. Perhexiline concentrations in plasma and heart tissue were determined by HPLC. RESULTS: Atrial biopsies were obtained from 94 patients and ventricular biopsies from 28 patients. The median plasma perhexiline concentration was within the therapeutic range at 0.24 mg l⁻¹ (IQR 0.12-0.44), the median atrial concentration was 6.02 mg kg⁻¹ (IQR 2.70-9.06) and median ventricular concentration was 10.0 mg kg⁻¹ (IQR 5.76-13.1). Atrial (r² = 0.76) and ventricular (r² = 0.73) perhexiline concentrations were closely and directly correlated with plasma concentrations (both P < 0.001). The median atrial : plasma ratio was 21.5 (IQR 18.1-27.1), ventricular : plasma ratio was 34.9 (IQR 24.5-55.2) and ventricular : atrial ratio was 1.67 (IQR 1.39-2.22). Using multiple regression, the best model for predicting steady-state atrial concentration included plasma perhexiline, heart rate and age (r² = 0.83). Ventricular concentrations were directly correlated with plasma perhexiline concentration and length of therapy (r² = 0.84). CONCLUSIONS: This study demonstrates that plasma perhexiline concentrations are predictive of myocardial drug concentrations, a major determinant of drug effect. However, net myocardial perhexiline uptake is significantly modulated by patient age, potentially via alteration of myocardial:extracardiac drug uptake.
Authors: Steven A Unger; Jennifer A Kennedy; Kate McFadden-Lewis; Kirsty Minerds; Geraldine A Murphy; John D Horowitz Journal: J Cardiovasc Pharmacol Date: 2005-12 Impact factor: 3.105
Authors: J D Horowitz; M K Dynon; E Woodward; S T Sia; P S Macdonald; D J Morgan; A J Goble; W J Louis Journal: Circulation Date: 1986-05 Impact factor: 29.690
Authors: T L Wenger; D J Browning; C E Masterton; M B Abou-Donia; F E Harrell; R J Bache; H C Strauss Journal: Circ Res Date: 1980-06 Impact factor: 17.367
Authors: Liang-Han Ling; William Chik; Paula Averbuj; Purendra K Pati; Aaron L Sverdlov; Doan T M Ngo; Raymond G Morris; Benedetta C Sallustio; John D Horowitz Journal: Ther Drug Monit Date: 2011-04 Impact factor: 3.681
Authors: P L Cole; A D Beamer; N McGowan; C O Cantillon; K Benfell; R A Kelly; L H Hartley; T W Smith; E M Antman Journal: Circulation Date: 1990-04 Impact factor: 29.690
Authors: Cher-Rin Chong; Nigel E Drury; Giovanni Licari; Michael P Frenneaux; John D Horowitz; Domenico Pagano; Benedetta C Sallustio Journal: Eur J Clin Pharmacol Date: 2015-09-16 Impact factor: 2.953
Authors: Bimala Dhakal; Celine Man Ying Li; Runhao Li; Kenny Yeo; Josephine A Wright; Krystyna A Gieniec; Laura Vrbanac; Tarik Sammour; Matthew Lawrence; Michelle Thomas; Mark Lewis; Joanne Perry; Daniel L Worthley; Susan L Woods; Paul Drew; Benedetta C Sallustio; Eric Smith; John D Horowitz; Guy J Maddern; Giovanni Licari; Kevin Fenix Journal: Cancers (Basel) Date: 2022-02-18 Impact factor: 6.639